Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease.
Tong X, Song Y, Yin S, Wang J, Huang R, Wu C, Shi J, Li J.
Chin Med J (Engl). 2022 Jul 20;135(14):1653-1663. doi: 10.1097/CM9.0000000000002310.
PMID:35940901
Si-Wu-Tang attenuates hepatocyte PANoptosis and M1 polarization of macrophages in non-alcoholic fatty liver disease by influencing the intercellular transfer of mtDNA.
Ma Z, Xie K, Xue X, Li J, Yang Y, Wu J, Li Y, Li X.
J Ethnopharmacol. 2024 Jun 28;328:118057. doi: 10.1016/j.jep.2024.118057. Epub 2024 Mar 20.
PMID:38518965
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.
Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A.
Int J Mol Sci. 2016 Mar 9;17(3):355. doi: 10.3390/ijms17030355.
PMID:27005620
UCP1 governs liver extracellular succinate and inflammatory pathogenesis.
Mills EL, Harmon C, Jedrychowski MP, Xiao H, Garrity R, Tran NV, Bradshaw GA, Fu A, Szpyt J, Reddy A, Prendeville H, Danial NN, Gygi SP, Lynch L, Chouchani ET.
Nat Metab. 2021 May;3(5):604-617. doi: 10.1038/s42255-021-00389-5. Epub 2021 May 17.
PMID:34002097
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.
Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ, de Martel C.